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Background 
raumatic brain injury (TBI) is an important
clinical problem in the United States and worldwide, but
after almost 50 years of research, no safe, clinically effec-
tive treatment has been found that can reduce mortality
and morbidity and improve functional outcome. TBI has
received more attention recently because of its high inci-
dence in combat casualties in Iraq and Afghanistan. US
Department of Defense statistics indicate that as many
as 30% of wounded soldiers seen at Walter Reed Army
Hospital have suffered a TBI, a finding which has stim-
ulated government interest in developing a treatment for
this complex disorder. Both pediatric and geriatric TBIs
are also on the rise as children of both sexes become
more involved in contact sports and as the elderly live
longer, drive more, and become more susceptible to auto
accidents and falls. 
A neuroprotective treatment for stroke has also proven
elusive. Well over 100 clinical trials for this incapacitat-
ing disease have yielded little substantive benefit for
patients. Aside from tissue plasminogen activator (tPA),
which can be given to only about 3% to 5% of stroke
victims, and only in the first 3 to 4 hours after stroke
onset, nothing that shows any evidence of reduction of
infarct size and neuroprotection is available for clinical
use. 
352
Brief report
Copyright © 2011 LLS SAS.  All rights reserved
Keywords: traumatic brain injury; progesterone; neuroprotection
Author affiliations: Department of Emergency Medicine, Emory University,
Atlanta, Georgia, USA  
Address for correspondence: Donald G. Stein, PhD, Emory University, 1365 B Clifton
Rd, NE, Suite 5100, Atlanta GA 30322, USA
(e-mail: dstei04@emory.edu)
Although progesterone is critical to a healthy preg-
nancy, it is now known to have other important func-
tions as well. Recent research demonstrates that this
hormone is also a potent neurosteroid that can protect
damaged cells in the central and peripheral nervous sys-
tems and has rapid actions that go well beyond its
effects on the classical intranuclear progesterone recep-
tor. Based on years of preclinical research demonstrat-
ing its safety and effectiveness in animal models of cen-
tral nervous system injury, the hormone was recently
tested in two Phase II clinical trials for traumatic brain
injury (TBI). A US National Institutes of Health-spon-
sored, nationwide Phase III clinical trial is now evaluat-
ing progesterone for moderate-to-severe TBI in 1200
patients. An industry-sponsored Phase III international
trial is also under way, and planning for a trial using
progesterone to treat pediatric brain injury has begun.
Preclinical data suggest that progesterone may also be
effective in stroke and some neurodegenerative disor-
ders.
© 2011, LLS SAS Dialogues Clin Neurosci. 2011;13:352-359.
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Progesterone as a treatment 
for brain injury?
Progesterone (PROG) is the bright exception to this
grim picture. A search of PubMed using the keywords
“progesterone, brain injury” yields over 200 publications
from more than 25 independent laboratories around the
world using 22 different injury models demonstrating
that PROG treatment can have beneficial effects lead-
ing to substantial and sustained improvements in cyto-
logical, morphological and functional outcomes. 
We now know that PROG given to both males and
females after central nervous system (CNS) injury can:
cross the blood-brain barrier (BBB)
1,2 and reduce
edema levels
3-5; reduce lipid peroxidation and iso-
prostanes, which contribute to post-injury ischemic
conditions
6; generate metabolites which reduce
proapoptotic and increase antiapoptotic enzymes
7 and
decrease the expression of proinflammatory genes and
their protein products
8,9; modify the expression of vas-
cular endothelial growth factor (VEGF) and brain-
derived neurotrophic growth factor (BDNF)
10-13; influ-
ence the expression of aquaporins implicated in the
resolution of edema; protect neurons distal to the
injury which would normally die
14; and enhance oligo-
dendrocyte-induced remyelination in young and aged
rats with demyelinating disorders.
15,16 PROG has a sub-
stantial treatment window and can be given up to 24
hours after injury and still show beneficial effects in
animal and clinical TBI.
5,17 Importantly, it has been
shown to produce significant sparing of cognitive, sen-
sory, and spatial learning performance in mature and
aged rats following bilateral brain injuries.
18A number
of reviews discuss these data and highlight the fact that
PROG and its key metabolites play a critical role in
both normal development and repair of the CNS after
injury (see Figure 1 for a diagram of the metabolic
pathways of this hormone).
19-25
Thus far much of our group’s research on PROG and its
metabolites has focused on the treatment of TBI.
8,14,26-29
This line of research originated when we found that fol-
lowing bilateral contusion injury to the medial frontal
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Figure 1. Steps in the biosynthesis of progesterone and some of its metabolites.
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cortex (MFC) in young adult, male and female rats, 3 to
5 days of post-injury treatment with PROG significantly
reduced cerebral edema and improved spatial learning
and sensory performance compared with controls given
vehicle alone.
30,31
Progesterone tested successfully in 
two phase II clinical trials
The first successful clinical trial for the treatment of
TBI in more than 30 years of research was published
in 2007.
17This NINDS-sponsored, Phase IIa single-cen-
ter clinical trial for PROG in the treatment of moder-
ate-to-severe adult TBI found that the mortality rate
among patients given PROG intravenously for 3 days
post-injury was less than half that of controls (13.6%
versus 30.4%). Thirty-day functional outcomes for
moderately injured patients in the PROG group were
significantly better than those for the placebo group.
An NIH-appointed Data Safety Monitoring Board
found no serious adverse events attributable to PROG
treatment. A second independent, randomized double-
blind study from China tested PROG in 159 patients
with severe TBI given a course of intramuscular injec-
tions for 5 days. The investigators reported similar ben-
eficial outcomes on morbidity and mortality at both 30
days and 6 months after injury, again without any seri-
ous adverse events caused by the treatment.
32 A
National Institute of Neurological Disorders and
Stroke is supporting a Phase III, 31-center, double-
blind, randomized clinical trial for TBI which is now
enrolling patients across the United States (ProTECT
III: NCT00822900), and a second trial (SyNAPSe:
NCT01143064) is testing PROG in over 140 centers
worldwide. The 22-center Pediatric Emergency Care
Applied Research Network (PECARN) is in the early
stages of planning for a Phase I/II clinical trial using
PROG in brain-injured children. 
The continuing stream of positive results seem almost
too good to be true—especially in light of the history of
failures to find an effective neuroprotective agent. Some
investigators
25,33 have expressed concern that many, if not
most, preclinical animal studies in TBI lack direct trans-
lation to clinical relevance because they fail to meet cer-
tain standards similar to the Stroke Therapy Academic
Industry Roundtable (STAIR) recommendations.
34
While no one study may be able to meet all the STAIR
recommendations, it is important to note that in the
aggregate, the large number of studies on PROG do, in
fact, meet such criteria as:
￿ Dose-response studies 
￿ Statistical power analyses to determine sample size(s)
￿ Comparison with other agents thought to be effective,
their antagonists, or knockout technologies to eluci-
date mechanisms
￿ Histological and functional outcome measurements to
examine short- and long-term effects
￿ Monitoring of relevant variables during surgery
￿ Studies in both males and females
￿ Studies in different models and species
￿ Replication of effects across laboratories
(These criteria are derived from recommendations pro-
posed by Loane and Faden.
33 They are similar to the
STAIR recommendations for use in testing new drugs
for the treatment of stroke).
Much of the growing support for PROG as a potential
treatment is likely based on its high safety profile and
evidence of efficacy in animal and human testing, but it
will be at least several more years before any conclu-
sions concerning its neuroprotective benefits in large-
scale testing can be fully confirmed.
Progesterone in stroke and 
neurodegenerative disorders
Stroke has overlapping pathophysiological mechanisms
with TBI, and the preclinical stroke data and recent
human studies in TBI support a potential role for PROG
in acute stroke. Recently we reported significant neuro-
protective effects of acute post-injury administration of
PROG in an adult rat model of permanent and transient
(2 h) middle cerebral artery occlusion stroke.
35,36 In dif-
ferent models of cerebral ischemia, PROG can signifi-
cantly reduce the area of necrotic cell death and improve
behavioral outcomes.
37 Our findings corroborated other
studies showing PROG to be neuroprotective following
global ischemia in cats,
38,39 and transient focal ischemia
in rats.
37,40 Several reviews and original research
papers
13,22,41-45 on the use of neurosteroids in stroke note
favorable outcomes in reduction of infarct size leading
to better functional status.
42
Nevertheless, TBI and stroke are very different diseases,
and there is no guarantee that PROG treatment will
work in human stroke. Before going forward to clinical
application, it will be important to determine whether
PROG treatment combined with tPA is safe and
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whether it has positive or negative outcomes. Our own
recent experiments suggest that PROG may upregulate
the expression of endogenous tPA and extend its win-
dow of effectiveness up to at least 6 hours, but this will
need to be confirmed by further research.
9 As of this
writing, no clinical trials using PROG or its metabolites
are being planned for stroke patients. 
There is now evidence that PROG and some of its
metabolites may be beneficial for other neurodegener-
ative disorders. Over the last 10 years, several groups
have reported that PROG exerts beneficial effects in
spinal cord injury, including enhanced remyelination and
improved motor function.
21,46-50 In a streptozotocin-
induced diabetic neuropathy model in rat, Leonelli et al
51
showed that treatment with PROG and some of its
metabolites sustains nerve conduction velocity, restores
skin innervation, and maintains sensitivity to thermal
stimulation. 
Treatment with various allopregnanolone (ALLO; a
metabolite of PROG) regimens in an animal model of
Niemann-Pick type C disease, an irreversibly fatal devel-
opmental neurodegenerative illness, may delay the onset
of symptoms (tremor, ataxia, weight loss).
52-54 Another
neurodegenerative condition, experimental autoimmune
encephalomyelitis (EAE), a model of multiple sclerosis,
may be amenable to treatment with PROG or its
metabolites.
55
From a psychiatric perspective there are some additional
advantages to considering PROG and its metabolites as
therapeutic agents following brain injury caused by
trauma or stroke. Both PROG and ALLO are present in
the serum and brain. ALLO is metabolized when PROG
is converted to dihydroprogesterone by 5α-reductase
and then into ALLO by 3α-hydroxysteroid dehydroge-
nase. ALLO is being evaluated because of its effects on
the expression and release γ-aminobutyric acid
(GABA)a, an inhibitory neurotransmitter which can
block or reduce post-injury seizure activity and its resul-
tant excitotoxicity.
56ALLO but not PROG is thought to
act directly as a ligand for the GABAa receptor and
some of its isoforms.
56,57
A major component of TBI and stroke is depression and
anxiety,
58-61 and there is growing evidence that adminis-
tration of PROG and ALLO may play a role in reduc-
ing TBI-related symptoms in animal models of these dis-
orders. The anxiolytic and antidepressant effects of
PROG and ALLO can even be observed in proges-
terone receptor (PR) knockout mouse models, suggest-
ing that the classical PRs are not necessarily implicated
directly in the beneficial outcomes of the treatment.
62
However, others have claimed that when some PR
antagonists have been used, depression-like behaviors
will become more obvious,
63 so the issue may be more
complex than one might think. Nonetheless, the litera-
ture can be taken to suggest that PROG and ALLO, act-
ing as neurosteroids through a variety of different recep-
tor mechanisms, do play a role in improving anxiety and
depression-like symptoms that follow CNS trauma. 
It is also interesting to note that cerebrospinal fluid
(CSF) levels of ALLO are decreased in patients diag-
nosed with PTSD or unipolar depression. Again, in ani-
mal models administration of ALLO (which is also syn-
thesized in the brain) reduces aggression, normalizes
fear responses, and decreases anxiety behaviors similar
to the effects of giving fluoxetine or similar drugs.
64,65
Finally, endogenous levels of pregnenalone (a precursor
of PROG and ALLO) have been associated with
increased analgesic and decreased nociceptive effects,
likely by modulating the GABAa receptor. In one clini-
cal study,
66 veterans of the Iraq war reporting low back
pain, chest pain, muscle soreness, and headaches had
their serum ALLO and DHEA levels measured by gas
chromatography (GC/MS) or radioimmunoassay. The
investigators found an inverse relationship between
ALLO levels and self-reports of low back pain. Taking
all the data together, it seems reasonable to suggest that
the clinical use of neurosteroids might provide a num-
ber of psychological benefits that are not currently avail-
able with other drugs used in the treatment of TBI or
stroke. The data showing that PROG and ALLO are
neuroprotective is now fairly extensive, but there is
growing evidence that, depending on dose and timing of
administration, these same treatments may also be able
to reduce some of the long-term consequences of brain
damage such as aggression, high anxiety, depression, and
cognitive disorders without a lot of concomitant nega-
tive side effects, while at other times, fluctuations in lev-
els of ALLO can increase negative mood symptoms.
67
The final story on the role of PROG and its metabolites
in altering mood and cognition in brain-injured patients
can be verified only by clinical trial evaluation involving
more chronic treatments and longer-term follow-up
studies than are typically done when studying the acute-
stage outcomes of TBI or stroke.
Besides its neuroprotective effects, PROG also shows
beneficial effects in other organs that are affected by brain
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Progesterone is a pleiotropic agent 
for brain injury
How can PROG have so many different salutary effects
on tissue repair? PROG is a naturally occurring hor-
mone found in both males and females, although healthy,
premenopausal females will have higher levels than
males. However, unlike other steroid hormones, PROG
is synthesized directly in the brain by oligodendrocytes
and neurons,
47,72 so it can be considered a “neurosteroid”
beyond its role as a sex hormone. 
In pregnant females, PROG levels increase 10- to 15-fold
and remain high throughout gestation, but in humans,
within 1 to 2 hours after parturition, levels drop precip-
itously. Why? It is becoming more evident that PROG’s
multiple mechanisms of action have evolved primarily
to protect the developing fetus from oxidative stress and
immune-inflammatory rejection reactions. The hormone
is now thought to play a critical role in neuronal-glial sig-
naling and normal neuronal development. Many of the
processes of tissue repair, including cells in the CNS,
recapitulate steps that take place during development.
73,74
Based on what we have seen following treatment with
PROG in adult subjects with brain injury, we hypothe-
size that its role in protecting the fetus during develop-
ment recapitulates its effects in the treatment of trau-
matic and degenerative disorders of the brain and CNS.
It is also important to note that PROG and its metabo-
lites such as ALLO are pleiotropic—they act at multiple
receptor sites, not just at the classical intranuclear PR.
These mechanisms are discussed in a number of recent
reviews that highlight the rapid, nongenomic actions of
PROG in the CNS and other tissue affected by injury or
degenerative diseases.
75,76
Conclusion
Many other drugs have failed in clinical trial because
they seem to act only at one or a few receptor sites, or
only affect the expression of genes implicated in the
injury cascade. To reiterate, it is suggested here that TBI
and stroke are systemic diseases that produce wide-
spread negative symptoms in many tissue and organ sys-
tems throughout the body. An agent or drug that acts
systemically to reduce the inflammatory cascade, while
at the same time providing trophic support to damaged
nerve cells, is more likely to have a beneficial outcome
than an agent that acts only at a single target in the
brain. This is where PROG seems to shine as a thera-
peutic agent.
Over 25 years of preclinical research by our laboratory
and now many others have identified and defined many
of the physiological mechanisms underlying PROG’s
benefits. Given its relatively high safety profile, ease of
administration, low cost, and ready availability, PROG
and its metabolites should be considered as a potential
treatment option—especially because in brain injury lit-
tle else is currently available. ❏
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¿Es la progesterona un candidato válido
como una nueva terapia para el daño 
cerebral traumático?
Aunque se sabe que la progesterona es clave para
un embarazo sano, ahora se le reconocen otras
importantes funciones. La investigación reciente
demuestra que esta hormona también es un
potente neuroesteroide que puede proteger las
células dañadas en el sistema nervioso tanto central
como periférico y tiene rápidas acciones que van
mucho más allá de sus efectos en el clásico receptor
de progesterona intranuclear. En base a años de
investigación preclínica que ha demostrado la segu-
ridad y eficacia de la hormona en modelos anima-
les de daño del sistema nervioso central, ésta se
probó recientemente en dos ensayos clínicos de
Fase II para daño cerebral traumático (DCT). En un
estudio financiado por los Institutos Nacionales de
Salud de los EE.UU., actualmente se está evaluando
la progesterona para el DCT moderado a grave en
1200 pacientes en un ensayo clínico de Fase III a
nivel nacional. También está en desarrollo un
ensayo internacional de Fase III financiado por la
industria y ha comenzado la planificación de un
ensayo que emplea progesterona para tratar daño
cerebral pediátrico. Los datos preclínicos sugieren
que la progesterona también puede ser efectiva en
los accidentes vasculares y en algunos trastornos
neurodegenerativos. 
La progestérone est-elle un bon candidat
comme nouveau traitement des lésions 
cérébrales traumatiques ?
La progestérone est indispensable à la grossesse
normale mais nous savons maintenant qu’elle a
aussi d’autres fonctions importantes. De récentes
recherches démontrent que cette hormone est aussi
un puissant neurostéroïde susceptible de protéger
les cellules des systèmes nerveux périphérique et
central altérées, et qu’elle est capable d’action
rapide allant bien au-delà de ses effets sur le clas-
sique récepteur intranucléaire à la progestérone.
Des années de recherche préclinique ont démontré
sa sécurité d’emploi et son efficacité dans des
modèles animaux de lésion du système nerveux
central. L’hormone a été récemment évaluée dans
deux études cliniques de phase 2 pour les lésions
cérébrales traumatiques (LCT). Une étude clinique
nationale de phase 3, financée par les National
Institutes of Health aux États-Unis,  évalue mainte-
nant la progestérone dans les LCT modérées à
sévères chez 1 200 patients. Une étude internatio-
nale de phase 3 financée par l’industrie est égale-
ment en cours ainsi que la planification d’une étude
utilisant la progestérone pour traiter les lésions
cérébrales chez l’enfant. Des données précliniques
suggèrent que la progestérone pourrait être aussi
efficace dans les accidents vasculaires cérébraux et
certains troubles neurodégénératifs.
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PAGES_ 12_AG_1004_BA.qxd:DCNS#50  30/08/11  16:04  Page 357Brief report
Copyright © 2011 LLS SAS.  All rights reserved 358
23. Junpeng M, Huang S, Qin S. Progesterone for acute traumatic brain
injury. Cochrane Database Syst Rev. 2011;1:CD008409.
24. Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection of sex steroids.
Minerva Endocrinol. 2010;35:127-143.
25. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treat-
ment of experimental brain injury; a systematic review. Brain. 2008;131(Pt
2):318-328.
26. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids
progesterone and allopregnanolone reduce cell death, gliosis, and func-
tional deficits after traumatic brain injury in rats. J Neurotrauma. 2005;22:106-
118.
27. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and proges-
terone decrease cell death and cognitive deficits after a contusion of the
rat pre-frontal cortex. Neuroscience. 2004;123:349-359.
28. Goss CW, Hoffman SW, Stein DG. Behavioral effects and anatomic cor-
relates after brain injury: a progesterone dose-response study. Pharmacol
Biochem Behav. 2003;76:231-242.
29. Stein DG. The case for progesterone. Ann N Y Acad Sci. 2005;1052:152-
169.
30. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects
against necrotic damage and behavioral abnormalities caused by traumatic
brain injury. Exp Neurol. 2002;178:59-67.
31. Attella MJ, Nattinville A, Stein DG. Hormonal state affects recovery
from frontal cortex lesions in adult female rats. Behav Neural Biol.
1987;48:352-367.
32. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the
administration of progesterone for patients with acute severe traumatic
brain injury: a randomized controlled trial. Crit Care. 2008;12:R61.
33. Loane DJ, Faden AI. Neuroprotection for traumatic brain injury: trans-
lational challenges and emerging therapeutic strategies. Trends Pharmacol
Sci. 2010;31:596-604.
34. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy
Academic Industry Roundtable (STAIR) recommendations for extended win-
dow acute stroke therapy trials. Stroke. 2009;40:2594-2600.
35. Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a proges-
terone metabolite, is more effective than progesterone in reducing corti-
cal infarct volume after transient middle cerebral artery occlusion. Ann
Emerg Med. 2006;47:381-389.
36. Sayeed I, Wali B, Stein DG. Progesterone inhibits ischemic brain injury
in a rat model of permanent middle cerebral artery occlusion. Restor Neurol
Neurosci. 2007;25:151-159.
37. Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after
transient middle cerebral artery occlusion in male rats. Brain Res.
1996;735:101-107.
38. Cervantes M, Gonzalez-Vidal MD, Ruelas R, Escobar A, Morali G.
Neuroprotective effects of progesterone on damage elicited by acute global
cerebral ischemia in neurons of the caudate nucleus. Arch Med Res.
2002;33:6-14.
39. Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Morali G,
Cervantes M. Progesterone: protective effects on the cat hippocampal neu-
ronal damage due to acute global cerebral ischemia. Arch Med Res.
1998;29:117-124.
40. Chen J, Chopp M, Li Y. Neuroprotective effects of progesterone after
transient middle cerebral artery occlusion in rat. J Neurol Sci. 1999;171:24-
30.
41. Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopreg-
nanolone attenuate blood-brain barrier dysfunction following permanent
focal ischemia by regulating the expression of matrix metalloproteinases.
Exp Neurol. 2010;226:183-190.
42. Wang J, Jiang C, Liu C, Li X, Chen N, Hao Y. Neuroprotective effects of
progesterone following stroke in aged rats. Behav Brain Res. 2010;209:119-
122.
43. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in trau-
matic and ischemic brain injury. In: Verhaagen J, Hol EM, Huitinga I, et al,
eds. Neurotherapy. Vol 175. New York, NY: Elsevier; 2009:219-237.
44. Jiang C, Wang J, Li X, Liu C, Chen N, Hao Y. Progesterone exerts neu-
roprotective effects by inhibiting inflammatory response after stroke.
Inflamm Res. 2009;58:619-624.
45. Ishrat T, Sayeed I, Atif F, Stein DG. Effects of progesterone administra-
tion on infarct volume and functional deficits following permanent focal
cerebral ischemia in rats. Brain Res. 2009;1257:94-101.
46. Labombarda F, Gonzalez SL, Lima A, et al. Effects of progesterone
on oligodendrocyte progenitors, oligodendrocyte transcription factors,
and myelin proteins following spinal cord injury. Glia. 2009;57:884-
897.
47. Baulieu EE. Neurosteroids: of the nervous system, by the nervous sys-
tem, for the nervous system. Recent Prog Horm Res. 1997;52:1-32.
48. Jung-Testas I, Baulieu EE. Steroid hormone receptors and steroid action
in rat glial cells of the central and peripheral nervous system. J Steroid
Biochem Mol Biol. 1998;65:243-251.
49. Jung-Testas I, Schumacher M, Robel P, Baulieu EE. Actions of steroid
hormones- and growth factors on glial cells of the central and peripheral
nervous system. J Steroid Biochem Mol Biol. 1994;48:145-154.
50. Schumacher M, Robel P, Baulieu EE. Development and regeneration of
the nervous system: a role for neurosteroids. Dev Neurosci. 1996;18:6-21.
51. Leonelli E, Bianchi R, Cavaletti G, et al. Progesterone and its derivatives
are neuroprotective agents in experimental diabetic neuropathy: a multi-
modal analysis. Neuroscience. 2007;144:1293-1304.
52. Ahmad I, Lope-Piedrafita S, Bi X, et al. Allopregnanolone treatment,
both as a single injection or repetitively, delays demyelination and enhances
survival of Niemann-Pick C mice. J Neurosci Res. 2005;82:811-821.
53. Langmade SJ, Gale SE, Frolov A, et al. Pregnane X receptor (PXR) acti-
vation: a mechanism for neuroprotection in a mouse model of Niemann-
Pick C disease. Proc Natl Acad Sci U S A. 2006;103:13807-13812.
54. Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neu-
rosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev.
2008;57:410-420.
55. Garay L, Deniselle MC, Lima A, Roig P, De Nicola AF. Effects of proges-
terone in the spinal cord of a mouse model of multiple sclerosis. J Steroid
Biochem Mol Biol. 2007;107:228-237.
56. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for cata-
menial epilepsy. Neurotherapeutics. 2009;6:392-401.
57. Frye CA. Hormonal influences on seizures: basic neurobiology. Int Rev
Neurobiol. 2008;83:27-77.
58. Reeves R, Panguluri R. Neuropsychiatric complications of traumatic
brain injury. J Psychosoc Nurs Ment Health Serv. 2011:1-9.
59. Hudak A, Warner M, Marquez de la Plata C, Moore C, Harper C, Diaz-
Arrastia R. Brain morphometry changes and depressive symptoms after trau-
matic brain injury. Psychiatry Res. 2011;191:160-165.
60. Kempf J, Werth E, Kaiser PR, Bassetti CL, Baumann CR. Sleep-wake dis-
turbances 3 years after traumatic brain injury. J Neurol Neurosurg Psychiatry.
2010;81:1402-1405.
61. Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS.
Rates of major depressive disorder and clinical outcomes following trau-
matic brain injury. JAMA. 2010;303:1938-1945.
62. Frye CA. Progesterone reduces depressive behaviour of young ovariec-
tomized, aged progestin receptor knockout, and aged wild type mice in the
tail suspension test. J Psychopharmacol. 2011;25:421-428.
63. Beckley EH, Scibelli AC, Finn DA. Progesterone receptor antagonist CDB-
4124 increases depression-like behavior in mice without affecting locomo-
tor ability. Psychoneuroendocrinology. 2010;36:824-833.
64. Pinna G. In a mouse model relevant for post-traumatic stress disorder,
selective brain steroidogenic stimulants (SBSS) improve behavioral deficits
by normalizing allopregnanolone biosynthesis. Behav Pharmacol.
2010;21:438-450.
65. Reddy DS. Neurosteroids: endogenous role in the human brain and
therapeutic potentials. Prog Brain Res. 2010;186:113-137.
66. Kilts JD, Tupler LA, Keefe FJ, et al. Neurosteroids and self-reported pain
in veterans who served in the U.S. Military after September 11, 2001. Pain
Med. 2010;11:1469-1476.
67. Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson IM.
Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J
Pharmacol. 2011;162:311-327.
68. Kuebler JF, Yokoyama Y, Jarrar D, et al. Administration of progesterone
after trauma and hemorrhagic shock prevents hepatocellular injury. Arch
Surg. 2003;138:727-734.
PAGES_ 12_AG_1004_BA.qxd:DCNS#50  30/08/11  16:04  Page 358www.dialogues-cns.org
Progesterone for brain injury - Stein Dialogues in Clinical Neuroscience - Vol 13 . No. 3 . 2011
359
69. Chen G, Shi J, Ding Y, Yin H, Hang C. Progesterone prevents traumatic
brain injury-induced intestinal nuclear factor kappa B activation and proin-
flammatory cytokines expression in male rats. Mediators Inflamm.
2007;2007:93431.
70. Pan DS, Liu WG, Yang XF, Cao F. Inhibitory effect of progesterone on
inflammatory factors after experimental traumatic brain injury. Biomed
Environ Sci. 2007;20:432-438.
71. Chen G, Shi JX, Qi M, Wang HX, Hang CH. Effects of progesterone on
intestinal inflammatory response, mucosa structure alterations, and apop-
tosis following traumatic brain injury in male rats. J Surg Res. 2008;147:92-
98.
72. Baulieu EE, Robel P, Schumacher M, eds. Neurosteroids: A New Regulatory
Function in the Nervous System. Totawa, New Jersey: Humana Press Inc.; 1999.
73. Teitelbaum P. Functional recovery after lesions of the nervous system.
V. Neural plasticity and behavioral recovery in the central nervous system.
The use of recovery of function to analyze the organization of motivated
behavior in the nervous system. Neurosci Res Program Bull. 1974;12:255-260.
74. Golani I, Wolgin DL, Teitelbaum P. A proposed natural geometry of
recovery from akinesia in the lateral hypothalamic rat. Brain Res.
1979;164:237-267.
75. Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action:
controversies, questions, and answers. Physiol Rev. 2003;83:965-1016.
76. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple
actions of steroid hormones--a focus on rapid, nongenomic effects.
Pharmacol Rev. 2000;52:513-556.
PAGES_ 12_AG_1004_BA.qxd:DCNS#50  30/08/11  16:04  Page 359